382 related articles for article (PubMed ID: 28224776)
21. Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients.
Seo E; Choi ES; Kim JH; Kim H; Koh KN; Im HJ; Lee J
PLoS One; 2021; 16(2):e0246191. PubMed ID: 33544726
[TBL] [Abstract][Full Text] [Related]
22. Induction of cytomegalovirus-specific T cell responses in healthy volunteers and allogeneic stem cell recipients using vaccination with messenger RNA-transfected dendritic cells.
Van Craenenbroeck AH; Smits EL; Anguille S; Van de Velde A; Stein B; Braeckman T; Van Camp K; Nijs G; Ieven M; Goossens H; Berneman ZN; Van Tendeloo VF; Verpooten GA; Van Damme P; Cools N
Transplantation; 2015 Jan; 99(1):120-7. PubMed ID: 25050468
[TBL] [Abstract][Full Text] [Related]
23. Reconstitution of CMV pp65 and IE-1-specific IFN-γ CD8(+) and CD4(+) T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT.
Tormo N; Solano C; Benet I; Nieto J; de la Cámara R; López J; Garcia-Noblejas A; Muñoz-Cobo B; Costa E; Clari MA; Hernández-Boluda JC; Remigia MJ; Navarro D
Bone Marrow Transplant; 2011 Nov; 46(11):1437-43. PubMed ID: 21243030
[TBL] [Abstract][Full Text] [Related]
24. Clinical Utility of QuantiFERON-Cytomegalovirus Test in Management of Kidney Transplant Recipients.
Tarasewicz A; Dębska-Ślizień A; Rutkowski B
Transplant Proc; 2016 Jun; 48(5):1650-3. PubMed ID: 27496465
[TBL] [Abstract][Full Text] [Related]
25. Kinetics of interferon-gamma producing cytomegalovirus (CMV)-specific CD4+ and CD8+ T lymphocytes and the risk of subsequent CMV viremia after allogeneic hematopoietic stem cell transplantation.
Eid AJ; Brown RA; Hogan WJ; Lahr BD; Eckel-Passow JE; Litzow MR; Razonable RR
Transpl Infect Dis; 2009 Dec; 11(6):519-28. PubMed ID: 19744286
[TBL] [Abstract][Full Text] [Related]
26. Assessing the risk of CMV reactivation and reconstitution of antiviral immune response post bone marrow transplantation by the QuantiFERON-CMV-assay and real time PCR.
Krawczyk A; Ackermann J; Goitowski B; Trenschel R; Ditschkowski M; Timm J; Ottinger H; Beelen DW; Grüner N; Fiedler M
J Clin Virol; 2018; 99-100():61-66. PubMed ID: 29331844
[TBL] [Abstract][Full Text] [Related]
27. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection.
Lilleri D; Fornara C; Chiesa A; Caldera D; Alessandrino EP; Gerna G
Haematologica; 2008 Feb; 93(2):248-56. PubMed ID: 18245650
[TBL] [Abstract][Full Text] [Related]
28. Functional specific-T-cell expansion after first cytomegalovirus reactivation predicts viremia control in allogeneic hematopoietic stem cell transplant recipients.
Ciáurriz M; Beloki L; Zabalza A; Bandrés E; Mansilla C; Pérez-Valderrama E; Lachén M; Rodríguez-Calvillo M; Ramírez N; Olavarría E
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921749
[TBL] [Abstract][Full Text] [Related]
29. The clinical and economic impact of cytomegalovirus infection in recipients of hematopoietic stem cell transplantation.
Webb BJ; Harrington R; Schwartz J; Kammerer J; Spalding J; Lee E; Dodds B; Kaufusi S; Goodman BE; Firth SD; Martin G; Sorensen J; Hoda D
Transpl Infect Dis; 2018 Oct; 20(5):e12961. PubMed ID: 29975816
[TBL] [Abstract][Full Text] [Related]
30. Coinfection with Human Cytomegalovirus Genetic Variants in Transplant Recipients and Its Impact on Antiviral T Cell Immune Reconstitution.
Smith C; Brennan RM; Tey SK; Smyth MJ; Burrows SR; Miles JJ; Hill GR; Khanna R
J Virol; 2016 Aug; 90(16):7497-507. PubMed ID: 27279616
[TBL] [Abstract][Full Text] [Related]
31. Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants.
Lacey SF; Gallez-Hawkins G; Crooks M; Martinez J; Senitzer D; Forman SJ; Spielberger R; Zaia JA; Diamond DJ
Transplantation; 2002 Sep; 74(5):722-32. PubMed ID: 12352893
[TBL] [Abstract][Full Text] [Related]
32. [Prevalence of human herpesvirus-6 in allogeneic hematopoietic stem cell transplant recipients in correlation with cytomegalovirus infection].
Wang LR; Dong LJ; Lu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1204-9. PubMed ID: 17204195
[TBL] [Abstract][Full Text] [Related]
33. Utility of the Enzyme-Linked Immunospot Interferon-γ-Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients.
Nesher L; Shah DP; Ariza-Heredia EJ; Azzi JM; Siddiqui HK; Ghantoji SS; Marsh LY; Michailidis L; Makedonas G; Rezvani K; Shpall EJ; Chemaly RF
J Infect Dis; 2016 Jun; 213(11):1701-7. PubMed ID: 26908740
[TBL] [Abstract][Full Text] [Related]
34. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation.
Micklethwaite KP; Clancy L; Sandher U; Hansen AM; Blyth E; Antonenas V; Sartor MM; Bradstock KF; Gottlieb DJ
Blood; 2008 Nov; 112(10):3974-81. PubMed ID: 18768783
[TBL] [Abstract][Full Text] [Related]
35. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function.
Nickel P; Bold G; Presber F; Biti D; Babel N; Kreutzer S; Pratschke J; Schönemann C; Kern F; Volk HD; Reinke P
Transpl Immunol; 2009 Mar; 20(4):238-42. PubMed ID: 19032982
[TBL] [Abstract][Full Text] [Related]
36. Early cytomegalovirus reactivation leaves a specific and dynamic imprint on the reconstituting T cell compartment long-term after hematopoietic stem cell transplantation.
Lugthart G; van Ostaijen-Ten Dam MM; Jol-van der Zijde CM; van Holten TC; Kester MG; Heemskerk MH; Bredius RG; van Tol MJ; Lankester AC
Biol Blood Marrow Transplant; 2014 May; 20(5):655-61. PubMed ID: 24462981
[TBL] [Abstract][Full Text] [Related]
37. Kinetics of inflammatory biomarkers in plasma predict the occurrence and features of cytomegalovirus DNAemia episodes in allogeneic hematopoietic stem cell transplant recipients.
Talaya A; Giménez E; Vinuesa V; Pérez A; Amat P; Piñana JL; Albert E; Hernández-Boluda JC; Solano C; Navarro D
Med Microbiol Immunol; 2019 Aug; 208(3-4):405-414. PubMed ID: 30911925
[TBL] [Abstract][Full Text] [Related]
38. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
[TBL] [Abstract][Full Text] [Related]
39. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
Neuenhahn M; Albrecht J; Odendahl M; Schlott F; Dössinger G; Schiemann M; Lakshmipathi S; Martin K; Bunjes D; Harsdorf S; Weissinger EM; Menzel H; Verbeek M; Uharek L; Kröger N; Wagner E; Kobbe G; Schroeder T; Schmitt M; Held G; Herr W; Germeroth L; Bonig H; Tonn T; Einsele H; Busch DH; Grigoleit GU
Leukemia; 2017 Oct; 31(10):2161-2171. PubMed ID: 28090089
[TBL] [Abstract][Full Text] [Related]
40. Monitoring of oral cytomegalovirus DNA shedding for the prediction of viral DNAemia in allogeneic hematopoietic stem cell transplant recipients.
Pascual T; Solano C; Torres I; Talaya A; Giménez E; Vinuesa V; Piñana JL; Hernández-Boluda JC; Pérez A; Navarro D
J Med Virol; 2018 Aug; 90(8):1375-1382. PubMed ID: 29663435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]